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ABSTRACT
Background: The 2010 inﬂuenza vaccination program
for children aged 6 months to 4 years in Western
Australia (WA) was suspended following reports of
severe febrile reactions, including febrile convulsions,
following vaccination with trivalent inactivated
inﬂuenza vaccine (TIV).
Methods: To investigate the association between
severe febrile reactions and TIV, three studies were
conducted: (i) rates of febrile convulsions within 72 h
of receiving TIV in 2010 were estimated by vaccine
formulation and batch; (ii) numbers of children
presenting to hospital emergency departments with
febrile convulsions from 2008 to 2010 were compared;
and (iii) a retrospective cohort study of 360 children
was conducted to compare the reactogenicity of
available TIV formulations.
Findings: In 2010, an estimated maximum of 18816
doses of TIV were administered and 63 febrile
convulsions were recorded, giving an estimated rate of
3.3 (95% CI 2.6 to 4.2) per 1000 doses of TIV
administered. The odds of a TIV-associated febrile
convulsion was highly elevated in 2010 (p<0.001) and
was associated with the vaccine formulations of one
manufacturerdFluvax and Fluvax Junior (CSL
Biotherapies). The risk of both febrile convulsions
(p<0.0001) and other febrile reactions (p<0.0001) was
signiﬁcantly greater for Fluvax formulations compared to
the major alternate brand. The risk of febrile events was
not associated with prior receipt of TIV or monovalent
2009 H1N1 pandemic vaccine. The biological cause of
the febrile reactions is currently unknown.
Interpretation: One brand of inﬂuenza vaccine was
responsible for the increase in febrile reactions,
including febrile convulsions. Until the biological
reason for this is determined and remediation
undertaken, childhood inﬂuenza vaccination programs
should not include Fluvax-type formulations and
enhanced surveillance for febrile reactions in children
receiving TIV should be undertaken.
INTRODUCTION
Infants and young children are known to have
an increased risk of severe disease from inﬂu-
enza A virus infection.
1 2 Inﬂuenza-related
hospitalisation rates for children less than
2 years of age are considerably higher than for
older children and are comparable to rates in
other groups considered to be at higher risk
for complications from inﬂuenza, including
the elderly.
3 Some countries recommend
universal annual vaccination for infants and
ARTICLE SUMMARY
Article focus
- Soon after commencement of the 2010 paedi-
atric inﬂuenza vaccination program in Western
Australia (WA), clinicians noted an apparent
increase in children presenting with fever,
vomiting and occasionally febrile convulsions,
which led to a temporary suspension of the WA
program for children under 5 years of age.
- Three separate analytical studies were under-
taken to determine the association between
severe febrile adverse events and administration
of the 2010 trivalent inactivated inﬂuenza vaccine
(TIV) to children aged 6 months through 4 years
in WA.
Key messages
- The estimated rate of febrile convulsions in
children aged under 5 years related to receipt of
the 2010 TIV was found to be 3.3 per 1000
doses, more than 200 times higher than the only
population-based published estimate.
- Of the two major brands of TIV used in the
program prior to its suspension, the elevated risk
of febrile convulsions and other febrile reactions
was found to be clearly associated with the
Fluvax and Fluvax Junior formulations, manufac-
tured by CSL Biotherapies; the reactions do not
appear to be associated with the other TIV
formulation.
- As the biological mechanism has, to date, not
been deﬁnitively identiﬁed, it seems reasonable
that countries implement paediatric vaccination
programs as usual using vaccine brands other
than those of CSL Biotherapies, and undertake
enhanced surveillance for febrile reactions and
other adverse events in all children under 5 years
of age receiving TIV.
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Open Access Researchchildren, including the USA, where vaccination is
recommended for children aged 6 months and above.
3
The Department of Health in the state of Western
Australia (WA) has been offering trivalent inactivated
inﬂuenza vaccine (TIV) to children aged 6 months to
4 years since 2008, following the deaths of three pre-
school-aged children from inﬂuenza the previous year.
Additionally, a new program providing TIV to children
with underlying medical conditions was implemented
throughout Australia in 2010.
4
The medical literature supports the safety of TIV in
young children.
5e8 Fever has been found to be a rela-
tively common adverse event in the few prospective
clinical trials that aim to determine the safety of TIV in
children, with rates ranging from 10% to 40%.
9e11 Few
studies large enough to accurately quantify the rate of
uncommon potential adverse events, including febrile
convulsions, following TIV administration have been
published. A recent analysis from the US Vaccine
Adverse Event Reporting System, which relies on passive
reports, found that in children less than 2 years of age,
seizures of any type, although rare, were the most
commonly reported serious adverse events.
6 A large
population-based study from the US Vaccine Safety
Datalink program found only one documented febrile
convulsion (which occurred on day 3) in the 3 days
following administration of 69359 doses of TIV to chil-
dren under 2 years of age (1.4 per 100000).
8
In 2010, distribution of TIV to immunisation providers
in WA (general medical practitioners and government
health services) began on 8 March and the childhood
inﬂuenza vaccination program was publicly launched on
19 March. During the week beginning 12 April 2010,
emergency department (ED) clinicians at a specialist
paediatric referral hospital noted an apparent increase in
children presenting with fever, vomiting and occasionally
febrile convulsions, usually within 12 h of vaccination with
TIV. Further reports led to a temporary suspension of the
WA program for children under 5 years of age on 22 April
2010 to allow time to investigate whether this signal
represented a true increase in adverse events, and
whether any increase was common to all TIV formulations
or speciﬁc to a particular formulation or batch(es). The
following day, the federal government suspended the use
of 2010 seasonal inﬂuenza vaccine for all children aged
5 years and under across Australia.
In Australia, there is a dual system for reporting
adverse events following immunisation (AEFI). In seven
of eight Australian states and territories, AEFI are noti-
ﬁable conditions, meaning there is a legal requirement
to report them to state/territory health authorites.
12
Vaccination providers and members of the public can
also report AEFI directly to an established national drug
adverse event reporting system.
13 Reports received by
either route are shared between national and state
bodies. Because data from such passive surveillance
systems for adverse events are limited due to lack of
a denominator, under-reporting and biased reporting,
we undertook a number of analytical studies to deter-
mine the association between severe febrile adverse
events and administration of the 2010 TIV to children
aged 6 months through 4 years in WA.
METHODS
Setting
WA has a total population of 2.3 million people, with
78% residing in the capital, Perth. An estimated 134000
children aged 6 months through 4 years were eligible for
free TIV in 2010.
Vaccines from three manufacturers were used in the
paediatric inﬂuenza vaccination program in 2010: CSL
Biotherapies (Parkville, Australia) supplied Fluvax
(0.5 ml) and the identically formulated Fluvax Junior
(0.25 ml), Solvay Pharmaceuticals (Pymble, Australia)
supplied Inﬂuvac, and Sanoﬁ Pasteur (Lyon, France)
supplied Vaxigrip. Fluvax Junior was indicated for use in
children aged 6 months to 3 years and the other
formulations for use in those aged 6 months and over.
All contained the three inﬂuenza haemagglutinin anti-
gens recommended by the WHO for the 2010 Southern
hemisphere inﬂuenza season (A/California/7/2009
(H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus
and B/Brisbane/60/2008-like virus).
14 The recom-
mended doses were 7.5 mg of each antigen for those
aged 6e36 months (0.25 ml vaccine) and 15 mg of each
antigen for 4-year-olds (0.5 ml vaccine). It is recom-
mended that children aged less than 10 years receive two
doses at least 1 month apart in the ﬁrst year of vaccina-
tion, and one dose in subsequent years. As fewer than
100 doses of Vaxigrip were given to children prior to
cessation of the program, this formulation was excluded
from assessment.
Ethics approval was not required for this study as the
data were gathered as part of a public health investigation.
Febrile convulsions following 2010 TIV vaccination
The period between the time TIV was made available to
providers in 2010 and the suspension of the program was
46 days. We deﬁned the investigation period as 49 days
(the 46-day period of the TIV program plus 3 days to
capture febrile convulsions occurring after the last TIV
vaccination). Febrile convulsions occurring outside the
ARTICLE SUMMARY
Strengths and limitations
- The major limitation of this study is the absence of reliable
prospective data from an established, timely surveillance
system designed to monitor adverse events resulting from
vaccination. Accordingly, several data sources were used to
gather numerator and denominator data, some already
established and some created ad hoc and requiring retrospec-
tive data collection.
- Its strengths are, ﬁrst, the consistency of ﬁndings using
different data sources and the strength of the statistical
associations found, and second, the fact that this is the ﬁrst
report of an elevated rate of severe febrile reactions to TIV in
children.
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Febrile reactions to TIV in WA childreninvestigation period were assumed to be unrelated to
2010 TIV.
Febrile convulsion cases during the investigation
period were identiﬁed through passive notiﬁcations to
the national AEFI reporting system and from ED diag-
nostic codes using the WA Emergency Department
Information System (EDIS). EDIS collects discharge
diagnosis data in near real-time from EDs at nine Perth
hospitals that have a combined catchment of approxi-
mately 1.76 million people (77% of the total population
of WA). Children aged 6 months through 4 years who
presented to an EDIS-enrolled hospital during the
investigation period and were assigned an ICD-10 code
of R56.0 (febrile convulsion)
15 were investigated.
To identify a possible temporal relationship between
EDIS-reported febrile convulsions and prior receipt of
TIV, we cross-checked the reported febrile convulsion
episodes with vaccination data recorded with the
Australian Childhood Immunisation Register (ACIR).
Veriﬁcation was also sought from the child’s primary
care givers and/or the child’s vaccine provider to
determine if the child had received TIV in the 72 h prior
to the febrile convulsion. The inﬂuenza vaccination
histories of cases were obtained from ACIR and the
child’s primary care giver or vaccine provider.
The case details for all 2010 R56.0-coded febrile
convulsions were identiﬁed through review of the case
records and details for any additional febrile convulsion
cases identiﬁed through passive reporting were collected
from interviews with the primary care giver or vaccination
provider using a standardised survey instrument. All
records were reviewed by one author (CB) to ensure
diagnostic accuracy. A febrile convulsion was deﬁned as
any generalised convulsive seizure (level 1, 2 or 3 according
to the Brighton Collaboration case deﬁnitions
16)t h a t
occurred in a febrile child (temperature on presentation
to a health practitioner >37.58C). A vaccine associated
febrile convulsion was deﬁned as any febrile convulsion
that occurred within 72 h of either the ﬁrst or subsequent
dose of TIV for which an alternative cause of fever could
not be identiﬁed either clinically or microbiologically.
A number of data sources were analysed to ascertain
the contribution of childhood infective causes to the
febrile convulsion cases over this time period: results of
microbiological work-up of the febrile convulsion cases,
presentations of gastroenteritis or inﬂuenza-like illness
to participants in the WA General Practice Sentinel
Surveillance Network and to EDIS-enrolled hospitals,
and review of microbiological results from the only
metropolitan paediatric hospital laboratory in Perth.
Rates of TIV-associated febrile adverse events in 2010
We obtained denominator data by surveying WA vaccine
providers following the suspension of the program using
a standardised form that requested information on
numbers of children vaccinated by age group (6e24
months, 3e4 years) and vaccine brand/formulation and
batch number. To account for possible under-ascertain-
ment of the number of vaccine doses administered due
to non-response by vaccine providers, the ﬁnal totals
were adjusted upwards by a factor of 1.4. This ﬁgure was
determined to provide the upper limit of the number of
doses that might really have been given. To estimate
rates of both convulsive and ‘other’ (non-convulsive)
febrile reactions per 1000 TIV vaccinations, cases of
febrile convulsions were determined from passive
reports and R56.0-coded presentations to EDIS-enrolled
hospitals (as described above), and cases of ‘other’
febrile reactions were derived from passive reports by
doctors, other immunisation providers and parents to
the AEFI reporting system.
Comparing TIV-associated febrile convulsions in
2008e2010
To examine whether the number of febrile convulsions
in children aged 6 months through 4 years had increased
in 2010, we compared the R56.0-coded visits to the nine
EDIS-enrolled hospitals for 2010 to those identiﬁed using
the same data extraction process for corresponding 49-
day periods following commencement of the paediatric
TIV program in both 2008 (from 31 March) and 2009
(from 17 February). As for febrile convulsions reported
in 2010, we cross-checked records of children with febrile
convulsions identiﬁed in 2008 and 2009 with the ACIR
and sought veriﬁcation from the child’s primary care
givers and/or the child’s vaccination provider.
Retrospective cohort study of paediatric TIV recipients
To assess the comparative reactogenicity of the three
main TIV formulations, we conducted a retrospective
cohort study to quantify the proportion of children
experiencing a range of post-TIV vaccination symptoms.
All children less than 5 years of age who had received the
2010 TIV at a large Perth public immunisation clinic
were stratiﬁed by age and brand of vaccine administered.
We then randomly selected 120 children from each of
the three vaccine groups: Fluvax, Fluvax Junior and
Inﬂuvac. The Fluvax and Inﬂuvac groups were stratiﬁed
by age, with 60 children aged #2 years and 60 aged
3e4 years selected from each group. All children in the
Fluvax Junior group were aged #2 years.
Primary care givers were interviewed by telephone
using a standardised questionnaire, which sought infor-
mation about symptoms in the 72 h following the 2010
TIV vaccination, body temperature measurement or self-
reported fever, healthcare attendance, and prior history
of vaccination with seasonal TIV or monovalent
pandemic inﬂuenza vaccine. If the child received two
doses of TIV, information was recorded about the ﬁrst
vaccination experience. Interviewers were blinded to the
brand/formulation of vaccine the child had received.
Statistical analysis
Simple descriptive statistics were generated using
Microsoft Excel or EpiInfo v 3.5.1 (CDC, Atlanta,
Georgia, USA). For comparisons of adverse events by
vaccine formulations, rates per 1000 vaccine doses and
95% CIs were determined. Relative risks (adjusted for
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c
2 statistics were calculated for the combined Fluvax
vaccines compared to Inﬂuvac. Fisher’s exact test was
used if expected cell frequencies were <5.
For analyses of adverse event data from the retro-
spective cohort study of TIV recipients from a large
immunisation clinic, we computed odds ratios
comparing events associated with combined Fluvax
vaccines to Inﬂuvac, and controlled for age (continuous)
using unconditional logistic regression. A multivariate
logistic regression model was also computed to deter-
mine if vaccine brand was still associated with ‘fever’ or
a ‘signiﬁcant febrile adverse event’ (deﬁned as fever
$398C recorded at home or during healthcare atten-
dance and/or rigors and/or a febrile convulsion) while
simultaneously controlling for three potential a priori
confounders: age, prior vaccination with monovalent
pandemic vaccine and prior vaccination with TIV, as
dichotomous variables.
RESULTS
Characteristics of febrile convulsion cases occurring in 2010
Based upon the uptake of inﬂuenza vaccine by children
in 2008 and 2009, it is estimated that 85% of children
vaccinated with the 2010 TIV resided in the catchment
area of the EDIS-enrolled hospitals. During the investi-
gation period, a total of 99 children aged 6 monthse4
years presented to Perth EDIS-enrolled hospitals and
were coded as R56.0 febrile convulsions. Of these, 38
(37.4%) occurred within 72 h of receipt of TIV. An
additional 25 TIV-associated febrile convulsion cases that
met diagnostic criteria were reported by ED clinicians,
primary care givers or vaccine providers to the national
AEFI reporting system, bringing the total number of
TIV-associated febrile convulsions in 2010 to 63. The TIV
brand/formulation could be determined for 62 of these
63 cases.
Of the 63 cases of febrile convulsions found to be
associated with TIV, vaccination data for 41 (65%) were
determined from cross-checking ACIR records (with
corroboration by their primary care giver and/or
immunisation provider), and the remaining 22 cases
(35%) had their inﬂuenza vaccination status ascertained
through interviews with their primary care giver and/or
immunisation provider alone. The number of doses
of vaccine cases had received in 2010 (either one or
two) were known for 57 of 63 (90%), and all of these
experienced their febrile convulsion after their ﬁrst
dose.
The demographic and clinical features of the 2010
cases derived from case record review and/or interviews
with their primary care givers or vaccine providers are
shown in table 1. The median time from receipt of TIV
to onset of symptoms in the febrile convulsion cases was
Table 1 Demographic and clinical details of 63 children aged 6 months to 4 years presenting with febrile convulsions within
72 h of receiving trivalent inactivated inﬂuenza vaccine during the investigation period, 8 March to 25 April 2010
Febrile convulsion presentations (n[63)
Demographics and past history Mean age (years) 1.85
Median age (years) 1.53
Male gender 38 (60.3%)
History of febrile convulsions 8 (12.7%)
History of seizures (other than febrile convulsions) 3 (4.8%)
History of AEFI 4 (6.3%)
Chronic medical condition* 7 (11.1%)
Symptoms on presentation Fever (self-report) 63 (100%)
Recorded temperature $388C 57 (90%)
Rigors 28 (44.4%)
Respiratory 12 (19.0%)
Vomiting 36 (57.1%)
Fatigue 22 (34.9%)
Diarrhoea 3 (4.8%)
Headache 3 (4.8%)
Rash 10 (15.9%)
Local swelling 3 (4.8%)
Clinical Admitted to hospital 28 (44.4%)y
Admitted to intensive care unit 2 (3.1%)
Sequelae 1 (1.6%)z
Time from vaccination to symptom onset Median time (h) 7.0x
Mean time (h) 8.9x
Onset within 12 h 93%x
*Chronic medical conditions included diabetes, chronic heart, respiratory, renal, neurological and blood disease, metabolic disease and
impaired immunity.
yMean length of stay 3 days; range 1e50 days.
zHypoxic ischaemic encephalopathy.
xData available for 57 cases.
AEFI, adverse event following immunisation.
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Febrile reactions to TIV in WA children7 h, with 93% having onset within 12 h. Vomiting was
a conspicuous symptom, reported by 57.1% of cases, but
local reactions were infrequent, with only 4.8% of cases
reporting swelling at the injection site.
Figure 1 shows the temporal distribution of febrile
convulsions from 1 January to 2 May 2010, and the
timing of the vaccination program. Presentations of
febrile convulsions increased following introduction of
the TIV program and decreased to baseline soon after its
suspension.
Presentations of gastroenteritis or inﬂuenza-like illness
to participants in the WA General Practice Sentinel
Surveillance Network and to EDIS-enrolled hospitals
over the study period indicated low rates of gastrointes-
tinal and respiratory viral illness in the community.
Paediatric hospital laboratory data did not show an
appreciable increase in childhood respiratory and
gastrointestinal pathogens. Only a minority of children
presenting to EDs with febrile convulsions in 2010 had
a microbiological investigation conducted, as an infec-
tive cause of the fever was not often suspected. Of those
who did have specimens taken, no pathogens were
detected that could explain their illness.
Rates of adverse events by vaccine
From the vaccine provider survey, it was estimated that
up to 18816 TIV vaccinations had occurred in children
aged 6 monthse4 years in WA prior to the program’s
suspension, giving a conservatively estimated rate of 3.3
(95% CI 2.6 to 4.2) febrile convulsions per 1000 doses.
The rate of febrile convulsions and other febrile
reactions, by vaccine brand and formulation, is shown in
table 2. There was a signiﬁcantly increased risk of both
febrile convulsions and ‘other’ febrile reactions associ-
ated with Fluvax, Fluvax Junior or both Fluvax prepara-
tions combined, compared to Inﬂuvac. Adjusted for age,
children receiving a Fluvax formulation were 14.8 times
(95% CI 8.3 to 26.7) more likely to have a reported other
febrile reaction than children receiving Inﬂuvac
(p<0.0001). Relative risk could not be calculated for
febrile convulsions, as no such events were reported for
the estimated 4720 doses of Inﬂuvac given in children
under 5 years of age, compared to an estimated rate of
4.4 per 1000 doses (95% CI 3.4 to 5.6) of Fluvax prod-
ucts (p<0.0001 for age adjusted comparison).
The risk of other febrile reactions appeared to be
consistent across batches of the adult Fluvax and Fluvax
Junior products (data not shown). However, there was
a signiﬁcantly increased rate of febrile convulsions
associated with Fluvax Junior (8.1 per 1000 doses (95%
CI 5.6 to 11.8)) versus Fluvax (3.3 per 1000 doses (95%
CI 2.4 to 4.6)): this was only partly explained by the fact
that Fluvax Junior was used more frequently in children
under 3 years of age, as the rate in children aged
3e4 years was also signiﬁcantly elevated when compared
to Fluvax. Although there was some variability in the
risk of febrile convulsions across batches of Fluvax (but
not for Fluvax Junior, as one batch dominated usage),
this did not reach statistical signiﬁcance (data not
shown).
Figure 1 Presentations of children under 5 years of age with febrile convulsions (ICD-10 code R56.0) to nine Perth hospital
emergency departments, 1 January to 2 May 2010. TIV, trivalent inactivated inﬂuenza vaccine.
Armstrong PK, Dowse GK, Efﬂer PV, et al. BMJ Open 2011;1:e000016. doi:10.1136/bmjopen-2010-000016 5
Febrile reactions to TIV in WA childrenHistorical comparison of febrile convulsions 2008e2010
There were 38 febrile convulsions temporally associated
with TIV identiﬁed by R56.0 coding in the nine EDIS-
enrolled hospital EDs in 2010, compared to only one in
2008 and none in 2009. The number of febrile convul-
sions of any cause during the investigation period was
greatest for 2010 (table 3). The proportion of febrile
convulsions temporally associated with TIV vaccination
was signiﬁcantly higher for 2010 compared to both 2008
and 2009 (p<0.001), and the odds of having a TIV-
associated febrile convulsion was signiﬁcantly elevated in
2010 (p<0.001).
Pattern of clinical reactions by vaccine formulation
The results of the retrospective cohort study are shown
in table 4. Of the 360 study subjects enrolled, 87.2% had
primary care givers who were contactable; there was no
signiﬁcant difference in the response rate across the
three vaccine formulation groups. The frequencies of
reported symptoms following vaccination with either
Fluvax vaccine formulation were similar and so were
combined for comparisons with Inﬂuvac. Fever, fatigue,
vomiting and rigors were each signiﬁcantly more
common in children who received a Fluvax vaccine
compared to those who received Inﬂuvac, both in
univariate analyses and in logistic regression analyses
controlling for age. There was no difference in the
frequency of other adverse events, including injection
site reactions, and no signiﬁcant differences in prior
history of vaccination with TIV or monovalent pandemic
inﬂuenza vaccine, between the Fluvax and Inﬂuvac
groups. In a multivariate logistic regression model,
‘signiﬁcant febrile adverse events’ were associated with
receipt of either Fluvax vaccine formulation (OR 8.9;
95% CI 3.1 to 25.7; p<0.0005) and younger age
(p¼0.024), but no association was found between these
events and receipt of seasonal inﬂuenza vaccine prior to
2010 or monovalent pandemic vaccine (p¼0.4 and
p¼0.8, respectively).
DISCUSSION
The suspension of the WA paediatric inﬂuenza vaccina-
tion program is the ﬁrst Australian vaccination program
of any type to be suspended in recent memory. This
analysis of available epidemiological data supports that
decision and provides four important observations. First,
the estimated rate of febrile convulsions related to
receipt of the 2010 TIV is far in excess of published rates
from post-marketing surveillance studies. The only
population-based published study that allows a rate of
TIV-associated febrile convulsions to be calculated,
indicates a rate of 1.4 per 100000 doses in children
under 2 years of age within 72 h of receipt of TIV,
8 which
compares to the estimated rate in our study of 330 per
100000 doses in children under 5 years of age. Another
report estimated the rate of febrile convulsions in 2010
in WA children under 5 years of age within 24 h of
receipt of TIV to be 900 per 100000 doses, and
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Febrile reactions to TIV in WA childrenapproximately 500 per 100000 doses for children from
other Australian states.
17
Second, there was a marked increase in the number of
TIV-attributable febrile convulsions reported from Perth
metropolitan EDs in 2010 compared to similar periods
in both 2008 and 2009, years for which the available data
indicate 32% and 34% of the 6-month through 4-year-
old cohort in the metropolitan area received at least one
dose of TIV, respectively.
18
Third, of the three brands of TIV used in the program,
the elevated risk of febrile convulsions and other febrile
reactions was found to be clearly associated with the
Fluvax and Fluvax Junior formulations, but not with
Inﬂuvac, for which no febrile convulsions were identiﬁed
in WA against an estimate of over 4000 doses given. The
excess of febrile reactions was not due to a particular
batch of the Fluvax product, as several batches were
implicated. The reason for the higher rate of febrile
convulsions associated with Fluvax Junior compared to
Fluvax is unclear, but it did not appear to be explained by
the younger age of Fluvax Junior recipients. As the rates
of non-convulsive febrile reactions were almost identical
for the two Fluvax formulations, it seems unlikely that the
apparent difference in the rate of febrile convulsions
represents a real difference between the formulations
related to some variation in concentration of whatever
factor is responsible for the excess in serious adverse
events. However, this possibility cannot be discounted.
Fourth, the febrile convulsions resulting from vacci-
nation with the Fluvax vaccines are unlikely to represent
a new, distinct clinical syndrome associated with the
vaccine. Rather, the data indicate that the febrile
convulsions were occurring against a background of
increased rates of febrile reactions following vaccination.
This conclusion is supported by the results of the vaccine
provider survey and the retrospective cohort study, which
both showed a clearly higher rate of febrile reactions in
recipients of Fluvax and Fluvax Junior compared to
those receiving Inﬂuvac. There was no evidence that the
elevated rate of febrile convulsions in 2010 resulted from
an increased incidence of childhood infections.
The major limitation of this study results from the
absence of reliable prospective data from an established,
timely surveillance system designed to monitor adverse
events resulting from vaccination. Accordingly, several
data sources were used to gather numerator and
denominator data, some already established and some
created ad hoc and requiring retrospective data collec-
tion. However, the strength of the statistical associations
found, together with the consistency of ﬁndings using
different data sources and the tight temporal association
of the febrile convulsions with TIV (93% of cases having
symptom onset within 12 h of vaccination), suggest the
conclusions are robust. Reporting bias relating to the
number of febrile convulsion cases being reported in
2010, or to Fluvax-related events in particular, cannot
explain this ﬁnding as there was no communication to
the public or the clinicians prior to the recognition of
the association and the program’s cessation.
This is the ﬁrst report of an elevated rate of severe
febrile reactions to TIV in children, and the biological
mechanism has, to date, not been deﬁnitively identiﬁed
despite an extensive laboratory investigation of Fluvax
and Fluvax Junior undertaken by the Therapeutic Goods
Administration, the Australian regulator of prescription
medicines including vaccines. These studies are
ongoing, but endotoxins or abnormal levels of whole
virus particles have not been identiﬁed. Pyrogenicity
studies in different animal models have shown
conﬂicting results. The Therapeutic Goods Administra-
tion has hypothesised that high content and enzyme
activity of neuraminidase in the H1N1 component of the
2010 TIV compared to previous years may be responsible
for different cytokine responses and the increased
pyrogenicity of the CSL vaccine.
17 In the meantime, the
Australian government recommended use of vaccines
other than the CSL products in children under 5 years of
age for the remainder of 2010
19 and in 2011
20, and the
Table 3 Presentations of febrile convulsions in children aged 6 months to 4 years to nine Perth hospital emergency
departments in the 49-day period following commencement of the trivalent inactivated inﬂuenza vaccination program,
2008e2010*
Year
Number of febrile convulsiony presentations within the
investigation periodz
OR of temporally relatedx
febrile convulsions
p Value for
difference Total
Not temporally
relatedx to TIV
Temporally
relatedx to TIV Unknown{
2008 74 70 1 3 Reference Reference
2009 68 65 0 3 0 (0e19) 0.34
2010 99 60 38 1 44 (6e894) <0.001
*Unadjusted estimates of number of TIV doses given were 26037 in 2008, 11909 in 2009 (both derived from program data) and 11243 in 2010
(derived from vaccine provider survey).
yICD-10 code R56.0 ‘febrile convulsion’. No febrile convulsions were recorded for children who had received monovalent H1N1 pandemic
inﬂuenza vaccine.
zThe 49-day period allows for febrile convulsion to develop 72 h after vaccination up to day 46.
xA temporal relationship is deﬁned as febrile convulsion occurring within 72 h of receiving TIV.
{‘Unknown’ if either not listed on the Australian Childhood Immunisation Register or uncontactable by telephone after four attempts, and
immunisation provider not known. ‘Unknowns’ were excluded from statistical analysis.
TIV, trivalent inactivated inﬂuenza vaccine.
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Febrile reactions to TIV in WA childrenUS Advisory Committee on Immunization Practices has
recommended that the CSL Biotherapies TIV marketed
in the USA (Aﬂuria) not be used in children aged from
6 months to 8 years.
21
The data from WA indicate that the elevated risk of
febrile adverse events was associated with TIV from
a single manufacturer. Experience in New Zealand, the
only other Southern hemisphere country to use Fluvax
and Fluvax Junior and vaccine from another manufac-
turer in 2010, corroborates this ﬁnding.
19 Furthermore,
and reassuringly, the low rate of febrile adverse
events and symptoms associated with Inﬂuvac in our
studies, and Vaxigrip in New Zealand,
19 indicates that
TIV containing pandemic (H1N1) 2009 antigen are not
inherently highly pyrogenic. Therefore, it seems
reasonable that countries implement paediatric vacci-
nation programs as usual using vaccine brands other
than those of CSL Biotherapies. However, until a cause
can be determined for the Australian ﬁndings, and
further national and international data are available, it is
recommended that enhanced surveillance be under-
taken for febrile reactions and other adverse events in all
children under 5 years of age receiving TIV.
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